New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
08:04 EDTTTPHTetraphase completes enrollment in lead-in portion of IGNITE 2 trial
Tetraphase Pharmaceuticals has completed patient enrollment in the lead-in portion of its IGNITE 2 clinical trial. This two-part Phase 3 clinical trial is studying the safety and efficacy of intravenous and oral formulations of eravacycline for the treatment of complicated urinary tract infections. The lead-in portion of this trial was designed to inform the selection of an oral dose to take forward into the pivotal portion of the Phase 3 trial; Tetraphase anticipates announcing top-line data in the third quarter of this year. In addition to IGNITE 2, Tetraphase is actively enrolling patients in IGNITE 1, a Phase 3 clinical trial evaluating the safety and efficacy of IV eravacycline in the treatment of cIAI. The Company expects to complete enrollment in this trial later this year and to announce top-line data in the first quarter of 2015.
News For TTPH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 23, 2015
13:52 EDTTTPHOne patient with link to CRE 'superbug' dead in North Carolina, CNN reports
Subscribe for More Information
February 19, 2015
09:03 EDTTTPHTetraphase, Achaogen jump after report of California 'superbug' outbreak
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use